Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan liposome vs nab-paclitaxel + gemcitabine in first-line pancreatic cancer
CTR20212175Phase 2Completed
- Sponsor
- CSPC Ouyi Pharmaceutical
- Start
- Sep 2021
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan liposome in pancreatic cancer (PC), sponsored by CSPC Ouyi Pharmaceutical. Started Sep 2021; status: completed.
02
Drugs
irinotecan liposome
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on CTR20212175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212175.